（文章来源：证券日报） 证券日报网讯 8月18日晚间，罗欣药业发布公告称，公司2025年第四次临时股东大会于2025年8月18日 召开，审议通过了《关于为控股子公司提供担保的议案》。 ...

证券代码：002793 股票简称：罗欣药业 公告编号：2025-072 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 特别提示： 1.本次股东大会未出现否决提案的情况； 2.本次会议未涉及变更以往股东大会已通过的决议的情况。 一、会议召开基本情况 1.会议召集人：罗欣药业集团股份有限公司（以下简称"公司"）董事会； 罗欣药业集团股份有限公司 2025 年第四次临时股东大会决议公告 2.会议主持人：公司董事长刘振腾先生； 3.现场会议召开时间：2025年8月18日（星期一）下午2:00； 4.现场会议召开地点：上海市浦东新区东育路255弄4号前滩世贸中心一期A 栋7层会议室； 5.网络投票时间： （1）通过深圳证券交易所交易系统进行网络投票的具体时间为2025年8月18 日的交易时间，即9:15-9:25，9:30-11:30和13:00-15:00； （2）通过深圳证券交易所互联网投票系统进行网络投票的开始时间为2025 年8月18日上午9:15，结束时间为2025年8月18日下午3:00。 6.召开方式：现场会议与网络投票相结合的方式。 7.本次股东大会 ...

关于罗欣药业集团股份有限公司 2025 年第四次临时股东大会 之法律意见书 致：罗欣药业集团股份有限公司 北京市金杜律师事务所上海分所（以下简称本所）接受罗欣药业集团股份 有限公司（以下简称公司）委托，根据《中华人民共和国证券法》（以下简称《证 券法》）、《中华人民共和国公司法》（以下简称《公司法》）、中国证券监督管理 委员会《上市公司股东会规则》（以下简称《股东会规则》）等中华人民共和国 境内（以下简称中国境内，为本法律意见书之目的，不包括中国香港特别行政 区、中国澳门特别行政区和中国台湾省）现行有效的法律、行政法规、规章和 规范性文件和现行有效的《罗欣药业集团股份有限公司章程》（以下简称《公司 章程》）有关规定，指派律师出席了公司于 2025 年 8 月 18 日召开的 2025 年第 四次临时股东大会（以下简称本次股东大会），并就本次股东大会相关事项出具 本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的以下文件，包括但不限 于： 1. 经公司 2025 年第三次临时股东大会审议通过的《公司章程》； 2. 公司于 2025 年 8 月 2 日刊登于深圳证券交易所（以下简称深交所）网 站的《罗欣 ...

金融界消息 截至2025年8月13日收盘，罗欣药业（002793）报收于5.86元，上涨0.34%，换手率2.79%， 成交量30.29万手，成交金额1.76亿元。 资金流向方面，今日主力资金净流出1476.41万元，占比成交额8.38%。其中，超大单净流出1719.62万 元、占成交额9.76%，大单净流入243.21万元、占成交额1.38%，中单净流出流入70.61万元、占成交额 0.4%，小单净流入1405.79万元、占成交额7.98%。 罗欣药业最新一期业绩显示，截至2025一季报，公司营业总收入4.83亿元、同比减少29.91%，归属净利 润565.11万元，同比增长115.41%，扣非净利润66.90万元，同比增长101.72%，流动比率0.728、速动比 率0.519、资产负债率63.98%。 天眼查商业履历信息显示，罗欣药业集团股份有限公司，成立于1998年，位于临沂市，是一家以从事医 药制造业为主的企业。企业注册资本108758.8486万人民币，实缴资本108758.8486万人民币。公司法定 代表人为刘振腾。 通过天眼查大数据分析，罗欣药业集团股份有限公司共对外投资了6家企业，参与招投标 ...

Core Viewpoint - The article highlights the increasing instances of illegal share reductions by major shareholders in listed companies, emphasizing the need for stricter regulations to restore investor confidence and maintain market integrity [1][5]. Group 1: Instances of Illegal Share Reductions - Over 60 listed companies have announced illegal share reductions by shareholders this year, with violations including breach of commitments and failure to disclose [1]. - Notable cases include shareholders of Anbiping and Jiuliang Co. engaging in illegal reductions due to calculation errors and failure to disclose plans, amounting to approximately 28.77 million yuan and 2.009 million yuan respectively [2][3]. - The case of Guo Zilong from Jiuliang Co. is highlighted, where he reduced shares below the IPO price, violating his commitment [3]. Group 2: Regulatory Response - Regulatory bodies have intensified their crackdown on illegal share reductions, with over 50 companies facing penalties or regulatory actions this year [5][6]. - A logistics company's controlling shareholder was publicly reprimanded for failing to disclose a reduction plan, having sold 53.18 million shares, amounting to 264 million yuan [6]. - The Shenzhen Stock Exchange imposed trading restrictions on shareholders involved in illegal reductions, aiming to uphold market order and protect minority investors [7]. Group 3: Motivations Behind Illegal Reductions - Major shareholders often possess information advantages, allowing them to exploit market conditions for profit through illegal reductions [4]. - The potential for significant financial gain serves as a strong motivation for these shareholders to engage in such practices [4]. Group 4: Market Impact - The prevalence of illegal share reductions undermines the image of companies and their management, negatively affecting investor confidence in the secondary market [1][5]. - Stricter regulations are seen as essential for creating a transparent and orderly market environment, which is crucial for attracting long-term investments [7].

Group 1 - The stock price of Luoxin Pharmaceutical is reported at 5.95 yuan as of August 6, 2025, reflecting a decline of 1.49% from the previous trading day [1] - The trading volume on the same day reached 725,895 hands, with a total transaction amount of 435 million yuan, and a price fluctuation of 5.30% [1] - Luoxin Pharmaceutical operates in the chemical pharmaceutical industry, focusing on drug research, production, and sales, with product lines including anti-infection, digestive system, and respiratory system medications [1] Group 2 - The number of shareholders in Luoxin Pharmaceutical significantly increased by 31,700 from July 18 to July 31, 2025, marking a growth rate of 88.04% [1] - As of July 31, 2025, the total number of shareholders reached 67,800, with an average market value of circulating shares held by each shareholder at 104,200 yuan [1] - On August 6, 2025, the net outflow of main funds for Luoxin Pharmaceutical was 26.09 million yuan, with a cumulative net outflow of 22.39 million yuan over the past five days [1]

New Stock Issuance - The new stock issuance for Zhigao Machinery (证券代码: 920101) is priced at 17.41 CNY per share, effective from August 5, 2025[1] - China Heavy Industry (证券代码: 601989) has a cash option declaration period from August 13, 2025[1] - China Shipbuilding (证券代码: 600150) has a buyback request period from August 13 to August 15, 2025[1] Offer and Acquisition Periods - Shenkou Co., Ltd. (证券代码: 002633) has a tender offer period from July 29 to August 27, 2025[1] - ST Kelly (证券代码: 300326) has a tender offer period from July 17 to August 15, 2025[1] - Happiness Blue Ocean (证券代码: 300528) has a significant announcement on July 30, 2025[1] Market Volatility - There are reports of severe abnormal fluctuations for Tibet Tourism (证券代码: 600749) as of July 31, 2025[1] - ST Suwu (证券代码: 600200) also reported significant volatility on July 30, 2025[1] - The stock of ST YaTai (证券代码: 000691) is under observation for abnormal trading activities as of August 5, 2025[1]

Core Viewpoint - 罗欣药业's stock price experienced a decline on August 4, closing at 6.13 yuan, down 0.22 yuan or 3.46% from the previous trading day [1] Group 1: Stock Performance - On August 4, the stock opened at 6.23 yuan, reached a high of 6.53 yuan, and a low of 6.03 yuan, with a trading volume of 1.0818 million hands and a transaction amount of 672 million yuan [1] - The stock showed rapid fluctuations during the day, with a rebound of over 2% within 5 minutes at 9:36 AM, reaching 6.5 yuan, followed by a decline of over 2% within 5 minutes at 9:43 AM, dropping to 6.26 yuan [1] Group 2: Capital Flow - On August 4, the net inflow of main funds was 13.1726 million yuan, accounting for 0.2% of the circulating market value [1] - Over the past five trading days, the cumulative net inflow of main funds was 25.3391 million yuan, representing 0.38% of the circulating market value [1] Group 3: Company Overview - 罗欣药业 operates in the chemical pharmaceutical industry, focusing on the research, production, and sales of pharmaceutical products [1] - The company's product line includes medications for anti-infection, digestive system, and respiratory system [1]

Group 1: New Stock Offerings - Shenke Co., Ltd. (002633) has a tender offer period from July 29, 2025, to August 27, 2025[1] - ST Kelly (300326) has a tender offer period from July 17, 2025, to August 15, 2025[1] - ST Zitian (300280) has a tender offer period ending on July 21, 2025[1] Group 2: Market Alerts - Xizang Tourism (600749) reported severe abnormal fluctuations on July 31, 2025[1] - Tianlu Convertible Bonds (110060) announced significant market activity on July 30, 2025[1] - ST Suwu (600200) experienced unusual trading patterns on July 30, 2025[1] Group 3: Additional Announcements - Happiness Blue Ocean (300528) issued a notice on July 30, 2025, regarding market conditions[1] - Common Pharmaceutical (300966) provided updates on August 1, 2025, related to stock performance[1] - Dongjie Intelligent (300486) released a statement on August 1, 2025, concerning market volatility[1]

每经AI快讯，罗欣药业（SZ 002793，最新价：6.09元）8月1日晚间发布公告称，公司第五届第二十七 次董事会会议于2025年8月1日在山东省临沂高新技术产业开发区罗七路管理中心三楼会议室和上海市浦 东新区前滩世贸中心会议室以现场表决和通讯表决相结合的方式召开。会议审议了《关于为控股子公司 提供担保的议案》等文件。 每经头条（nbdtoutiao）——"我们也深陷残酷价格战"！德资巨头中国区高管警告：智驾绝不能免费， 否则会给全行业带来灾难 （记者 王晓波） 2024年1至12月份，罗欣药业的营业收入构成为：医药工业占比89.02%，医药商业占比9.74%，其他业 务占比1.24%。 ...